AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 241 min read$CRSP

KASINGER JAMES R. sold $626K of CRSP

KASINGER JAMES R. (General Counsel and Secretary) sold 10,400 shares of CRISPR Therapeutics AG (CRSP) at $60.24 ($0.63M total) on 2026-09-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KASINGER JAMES R.
Published Sep 24, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 10:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRSP
Bearish
medium confidence
Mentioned
$CRSP
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPBearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, offering fresh data for traders.

02

Market read

Small insider sale may cause modest short-term price pressure but unlikely to move the broader market.

03

What to watch

Potential upcoming clinical data could offset negative sentiment.

Relevance 4/10Novelty 4/10Timing: filed Sep 24 2026

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on officer holdings.

Company-level read

Ticker impact

$CRSPBearishMedium confidence
Context

General Counsel James R. Kasinger sold 10,400 shares for $626,459 via a 10b5-1 plan.

Expected impact

Potential short-term dip of 1-2% as market digests insider sell.

Evidence & confidence

Sale size is modest but involves a senior officer; market may view as a slight bearish cue.

Market effects

Sector

Limited impact on biotech sector; similar insider sales are common.

Regional

No significant regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not reflect company fundamentals.

Key entities

  • Officer
    James R. Kasinger

    General Counsel and Secretary of CRISPR Therapeutics AG.

  • Company
    CRISPR Therapeutics AG

    Biotech firm developing CRISPR gene-editing therapies.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRSP insider trading history →

Related articles

OCT 28
$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

stocktwits.com2 min
OCT 24
$CRSPMedAI 8/10

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

CRISPR Therapeutics (CRSP) reports promising Phase 1a trial data for CTX310, a gene-editing therapy for high LDL and TG levels, with potential market of 40M+ U.S. patients. The company also shares Casgevy's rights with Vertex (VRTX). CTX310's Phase 1b results are expected in November. CRISPR's pipeline includes other candidates like CTX611, but faces risks of setbacks and market adoption challenges.

finance.yahoo.com3 min